Compare functional testosterone suppression with gland disorders, including how repeat tests, underlying causes and fertility shape clinical care.
Functional testosterone suppression and organic testicular or pituitary disorders can both produce low testosterone, but distinguishing them affects whether care targets contributing conditions or established gland disease.
This article is for informational purposes only and is not medical advice. Diagnosis and treatment decisions belong with a qualified clinician.
The European Association of Urology (EAU) guideline describes functional hypogonadism as testosterone deficiency without recognized organic changes in the hypothalamic-pituitary-testicular axis. That axis links stimulation from the hypothalamus and pituitary with testosterone production in the testes.
In functional hypogonadism, other health conditions can affect how this system works. The guideline commonly associates this pattern with coexisting illness rather than an identified structural gland disorder.
Its listed contributors include:
This list explains why functional suppression should not be reduced to a label about lifestyle. Illness and medicines belong in the assessment alongside weight-related hormone questions.
The key diagnostic boundary is that functional hypogonadism is a diagnosis of exclusion. Organic causes must first be ruled out. Having obesity or another listed condition does not establish that it explains a particular man's result.
For readers, the useful distinction is between a possible contributor and a confirmed explanation. The clinician's task is to assess the whole pattern rather than infer the cause from body size or medical history alone.
Organic hypogonadism is also called classical hypogonadism. It involves congenital or acquired disease causing structural or irreversible impairment of the pituitary or testes. The EAU distinguishes this from functional suppression by the underlying gland disorder rather than by the testosterone result alone.
Primary hypogonadism means the problem is at the testes. Their ability to produce testosterone is impaired.
The guideline lists testicular trauma and orchitis among organic causes. It also includes chemotherapy-related injury among causes of hypogonadism.
Secondary hypogonadism means the testes receive inadequate stimulation from the hypothalamic-pituitary system. An organic pituitary disorder can produce this pattern.
Pituitary tumors and pituitary irradiation are among the organic causes listed by the EAU. Their significance is not simply that testosterone is low. The underlying disorder itself may need assessment and treatment.
A low testosterone concentration does not identify either type of disorder on its own. The clinical question is what mechanism explains the result and whether other findings support that explanation.
This comparison contains two different classification questions. Primary versus secondary describes where the problem lies. Functional versus organic describes the nature of the cause. A secondary pattern therefore does not automatically establish functional suppression.
The EAU starts diagnosis with a clinical syndrome: compatible symptoms together with biochemical evidence of testosterone deficiency. For late-onset hypogonadism, it calls for low morning total testosterone on at least two occasions using a reliable assay under fasting conditions.
That requirement keeps symptoms and repeat laboratory findings in the same assessment. A single low result is not a complete explanation for symptoms or proof of a gland disorder.
The guideline also advises against testosterone measurement during acute illness. Acute disease can be associated with functional suppression, so the circumstances of collection matter when interpreting a low testosterone result.
When testosterone is pathologically low, the EAU recommends measuring LH and FSH to help distinguish types of hypogonadism. These tests add information about the hormonal pattern rather than simply repeating the testosterone measurement.
The guideline recommends prolactin testing when secondary hypogonadism is accompanied by low sexual desire or other suggestive signs and symptoms. This is part of identifying an explanation that could alter care.
Further pituitary assessment is selective. The EAU recommends pituitary MRI when secondary hypogonadism occurs with:
These findings give clinicians a reason to investigate the pituitary itself. They do not mean that every low testosterone result requires a scan.
The guideline also calls for assessment of contributing diseases, drugs and substances. A useful clinical discussion therefore includes current illnesses and the medicines being taken, not just the latest laboratory value.
The practical question is not simply whether testosterone is low. It is whether the symptoms and testing support testosterone deficiency and what is driving that pattern.
According to the EAU, identifying the cause helps clinicians select appropriate treatment. That can mean addressing contributing conditions or treating a gland disorder. It can also involve considering testosterone therapy within an individual clinical assessment.
For men with hypogonadism who are overweight or obese, the guideline recommends lifestyle improvement and weight reduction before starting testosterone therapy. It also recommends treating coexisting conditions and withdrawing testosterone-impairing medicines when possible. Decisions about changing prescribed medicines remain with the treating clinician.
The size of the expected hormone change needs context. The EAU's evidence summary reports a small average testosterone increase of about 1-2 nmol/L with weight loss through calorie restriction and physical activity. It also describes evidence for combining lifestyle intervention with testosterone therapy as limited. These findings do not establish that lifestyle measures replace indicated treatment in every patient.
The same guideline notes evidence of symptom relief in symptomatic men with obesity who received testosterone therapy. Untreated men in the cited comparison did not experience that relief. It also identifies symptomatic men with testosterone below 12 nmol/L as potential candidates for therapy when specific contraindications are absent.
That is a clinical eligibility discussion rather than a rule for acting on a laboratory number. Symptoms and confirmed results still have to be considered with the cause and the person's treatment goals.
When a pituitary mass or hyperprolactinemia is identified, the guideline recommends treatment of the indicated underlying condition. Hyperprolactinemia means high prolactin. The care conversation must therefore include the gland disorder itself rather than stop at the testosterone result.
This prevents an unhelpful either-or framing. Addressing an underlying cause and assessing testosterone deficiency belong to the same care discussion, even though their roles differ. Testosterone therapy alone should not be assumed to address every cause of hypogonadism.
Fertility changes the discussion because testosterone supplied from outside the body suppresses gonadotropins and the body's own testosterone secretion. It also suppresses sperm production.
The EAU states that testosterone therapy is contraindicated for men seeking fertility treatment or wishing to father children. Fertility goals therefore need to be clear before treatment is considered.
For secondary hypogonadism when fertility is desired, the guideline describes gonadotropin treatment as a potential way to maintain testosterone and restore sperm production. This is a specialist treatment consideration rather than a self-directed alternative to TRT.
The important distinction is between treating testosterone deficiency and selecting an approach that also fits reproductive goals. Those goals can change which treatment conversation is appropriate even when the presenting concern is the same low hormone result.
A cause-based consultation can connect the findings with the proposed approach:
These questions do not select a treatment. They help clarify why the clinician is considering one approach rather than treating all low testosterone results as interchangeable.
Functional suppression and organic gland disease are best viewed within one cause-based assessment that connects symptoms with confirmed hormone findings and the goals of care.
Suppression linked to other health conditions is not the same explanation as gland disease, and Testostra addresses that distinction through education rather than diagnosis. Its evidence-led coverage helps men make sense of uncertainty about symptoms and their possible causes before discussing their concerns with a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra